Patents Examined by Dawanna Shar-Day White
  • Administration of aurora kinase inhibitor and chemotherapeutic agents
    Patent number: 12042499
    Abstract: Disclosed are methods for the treatment of cancer in patients in need of such treatment. The methods comprise administering to such a patient an Aurora kinase inhibitor such as 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoic acid or a pharmaceutically acceptable salt in combination with a platin. Also disclosed are medicaments for use in the treatment of cancer.
    Type: Grant
    Filed: April 2, 2020
    Date of Patent: July 23, 2024
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Jeffrey A. Ecsedy, Mengkun Zhang
  • Heterobicyclic compounds for inhibiting the activity of SHP2
    Patent number: 12037345
    Abstract: The invention provides a compound of formula (I): wherein Ring A, Q, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, X, a, b, c and d are as defined in the specification, useful for inhibiting the activity of SHP2.
    Type: Grant
    Filed: July 23, 2019
    Date of Patent: July 16, 2024
    Assignees: TAIHO PHARMACEUTICAL CO., LTD., OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Tadashi Shimamura, Ryo Kato, Risako Miura, Takashi Mita, Takahiro Ogawa, Yufu Sagara, Christopher Norbert Johnson, Steven Howard, James Edward Harvey Day, Jeffrey David St. Denis, John Walter Liebeschuetz
  • Inhibitors of human immunodeficiency virus replication
    Patent number: 11958834
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth:
    Type: Grant
    Filed: August 7, 2019
    Date of Patent: April 16, 2024
    Assignee: VIIV Healthcare UK (No.5) Limited
    Inventors: Makonen Belema, Manoj Patel
  • Pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives useful in the treatment of psoriasis and systemic lupus erythematosus
    Patent number: 11891400
    Abstract: The present invention provides a compound of Formula I: wherein R is methyl or ethyl; or a pharmaceutically acceptable salt thereof useful for treating psoriasis or systemic lupus erythematosus.
    Type: Grant
    Filed: September 4, 2019
    Date of Patent: February 6, 2024
    Assignee: Eli Lilly and Company
    Inventors: Zhaogen Chen, Jon Andre Erickson, Gaiying Zhao